[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-356134-en":59,"doc-seo-356134-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},356134,962090893776,"LangkahRina","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Annual report of national clinical database-breast cancer registry in 2023 - systemic therapy for small breast cancer","Annual report of the National Clinical Database–Breast Cancer Registry (NCD-BCR) by the Japanese Breast Cancer Society summarizes nationwide breast cancer statistics for patients registered in Japan in 2023. Among 107,372 patients across 1,317 institutions, 99.3% were female with a median age of 62 years. Stage distribution was stage 0 to IV, with receptor positivity and treatment patterns (surgery, sentinel lymph node biopsy, radiotherapy, and systemic therapy) reported, emphasizing size-dependent and subtype-specific systemic therapy use and risk-adapted strategy in Japan.","Breast Cancer (2026) 33:947–953  \n[https://doi.org/10.1007/s12282-026-01881-0](https://doi.org/10.1007/s12282-026-01881-0)  \nSPECIAL ARTICLE  \nAnnual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancer  \nShinsuke Sasada1 · Hiraku Kumamaru2 · Naoko Kinukawa2 · Takayuki Iwamoto3 · Masahiro Kawashima4 · Takaaki Konishi5,6 · Shigehira Saji7 · Naoko Sanuki8 · Kenta Tanakura9 · Masayuki Nagahashi10 · Minoru Miyashita11 · Masayuki Yoshida12 · Takayuki Kinoshita13 · Yasuaki Sagara14 · Naoki Niikura15 · Takanori Ishida11 · Naruto Taira3  \nReceived: 28 January 2026 / Accepted: 1 June 2026 / Published online: 12 June 2026 © The Author(s) 2026  \nAbstract  \nThis annual report of the National Clinical Database-Breast Cancer Registry (NCD-BCR) by the Japanese Breast Cancer Society presents nationwide breast cancer statistics for patients registered in Japan in 2023. Among 107,372 patients with breast cancer at 1317 institutions, 99.3% were females with a median age of 62 years. The distribution of the clinical stages was as follows: stage 0 (15.5%); stage I (42.1%); stage II (31.1%); stage III (7.0%); and stage IV (2.1%) . Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) positivity was observed in 78.9%, 70.0%, and 13.3% of patients, respectively. Among 102,717 patients without distant metastases, 41.2% underwent breast-conserving surgery, 76.5% underwent sentinel lymph node biopsy, and 6.0% underwent breast reconstruction. The distribution of radiotherapy was as follows: 75.2% received whole-breast irradiation, 15.7% chest-wall irradiation, and 20.7% regional irradiation. Among the 13,061 patients with pT1abN0M0 breast cancer, comprising 10,819 hormone receptor [HR]-positive/HER2-negative, 1479 HER2-positive and 763 HR-negative/HER2-negative individuals, 92.4% of HR-positive/HER2-negative patients received endocrine therapy, 46.9% of HER2-positive patients received chemotherapy and/or anti-HER2 therapy, and 31.2% of HR-negative/HER2-negative patients received chemotherapy. This annual report provides a nationwide overview of contemporary systemic therapy patterns in small breast cancer and highlights size‑dependent and subtype‑specific use of systemic therapy in Japan, reflecting a risk‑adapted treatment strategy.  \nKeywords Japanese breast cancer society · Registry · National clinical database · Annual report · Breast neoplasm  \n􀀍 Shinsuke Sasada[shsasada@hiroshima-u.ac.jp](shsasada@hiroshima-u.ac.jp)  \n1 Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Hiroshima, Japan  \n2 Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan  \n3 Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Okayama, Japan  \n4 Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan  \n5 Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan  \n6 Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan  \n7 Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan  \n8 Department of Radiology, Keio University School of Medicine, Tokyo, Japan  \n9 Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, Tokyo, Japan  \n10 Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, Nishinomiya, Japan  \n11 Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan  \n12 Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan  \n13 Department of Breast Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan  \n14 Department of Breast and Thyroid Surgical Oncology, Hakuaikai Medical Corporation, Sagara","cbCailuR7RtdRWXE","https://ap.wps.com/l/cbCailuR7RtdRWXE","pdf",784747,15,"English","en",105,"# Abstract\n## Registry overview and patient cohort (2023)\n## Tumor stage, receptor status, and key systemic therapy patterns","[{\"question\":\"What dataset and population does the 2023 annual report cover?\",\"answer\":\"The report summarizes nationwide breast cancer statistics from the National Clinical Database–Breast Cancer Registry (NCD-BCR) for patients registered in Japan in 2023.\"},{\"question\":\"How are clinical stages and receptor statuses presented?\",\"answer\":\"It reports the distribution of clinical stages (stage 0 through stage IV) and the proportions of estrogen receptor, progesterone receptor, and HER2 positivity.\"},{\"question\":\"What systemic therapy information is highlighted for small breast cancer?\",\"answer\":\"For pT1abN0M0 cases, it describes endocrine therapy, chemotherapy, and anti-HER2/chemotherapy use by hormone-receptor/HER2 subtypes, emphasizing size- and subtype-specific patterns.\"}]","Annual report of national clinical database-breast cancer registry in 2023 - systemic therapy for small breast cancer | PDF",1790123568,18,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dc138271a25c56ad9c94b5537e9ea72.webp",983,1305,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1df891b3983155ecb97f5b7db3506ba9.webp",982,1304,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b2b0e475d98dc717c9f5a99df78cbda.webp",981,1303,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cefd510ae5ebd4b04590813b8eea8a2c.webp",980,1301,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"annual-report-of-national-clinical-database-breast-cancer-registry-in-2023-systemic-therapy-for-small-breast-cancer","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/annual-report-of-national-clinical-database-breast-cancer-registry-in-2023-systemic-therapy-for-small-breast-cancer/356134/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/annual-report-of-national-clinical-database-breast-cancer-registry-in-2023-systemic-therapy-for-small-breast-cancer/356134.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":72},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What dataset and population does the 2023 annual report cover?","Question",{"text":146,"@type":147},"The report summarizes nationwide breast cancer statistics from the National Clinical Database–Breast Cancer Registry (NCD-BCR) for patients registered in Japan in 2023.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How are clinical stages and receptor statuses presented?",{"text":151,"@type":147},"It reports the distribution of clinical stages (stage 0 through stage IV) and the proportions of estrogen receptor, progesterone receptor, and HER2 positivity.",{"name":153,"@type":144,"acceptedAnswer":154},"What systemic therapy information is highlighted for small breast cancer?",{"text":155,"@type":147},"For pT1abN0M0 cases, it describes endocrine therapy, chemotherapy, and anti-HER2/chemotherapy use by hormone-receptor/HER2 subtypes, emphasizing size- and subtype-specific patterns.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790471433]